FAQ on GeoVax's Needle-Free, Self-Administered GEO-MVA Vaccine Research Program

What is the main purpose of GeoVax’s research program?

The main purpose is to evaluate the immunogenicity and stability of the GEO-MVA vaccine delivered via Vaxxas’ HD-MAP platform, aiming to develop a needle-free, thermostable vaccine for global immunization and pandemic response.

Why is this research significant?

This research could lead to a vaccine that is easier to distribute and administer, especially in low- and middle-income countries, by eliminating the need for needles and refrigeration, and potentially enhancing immunogenicity.

How does the HD-MAP platform work?

The HD-MAP platform delivers the vaccine through a high-density microarray patch applied to the skin, offering a needle-free method that may improve immunogenicity and thermostability.

Who is involved in this research program?

GeoVax Labs, Inc., Vaxxas, and researchers at the University of Queensland, led by A/Prof David Muller and Dr. Chris McMillan, are involved in this research program.

When is this research taking place?

The research was announced on July 28, 2025, and is currently being conducted under a research agreement between GeoVax and UniQuest Pty Limited.

Where is this research applicable?

This research is applicable globally, with particular benefits for pandemic response, biodefense stockpiling, and immunization programs in low- and middle-income countries.

What are the potential advantages of the HD-MAP platform over traditional vaccine delivery methods?

Potential advantages include self-administration, increased patient acceptance, higher immunogenicity, thermostability, elimination of sharps waste, and faster deployment in emergency settings.

How does this research impact future vaccine development?

Successful research could streamline the development of thermostable, needle-free vaccines, making them more accessible and effective for global immunization efforts and pandemic preparedness.

What should people know about this research?

People should know that this research represents a significant step towards more accessible and efficient vaccine delivery methods, with potential benefits for global health security.

Who can I contact for more information about this research?

For more information, you can contact GeoVax Labs, Inc. directly, as they are the primary entity behind this research program.